A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

NCT05650385 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms Malignant

Interventions

DRUG: B1962

Sponsor

Tasly Biopharmaceuticals Co., Ltd.